Literature DB >> 18081235

Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: challenging the boundaries.

A Z Khan1, V Pitsinis, S S Mudan.   

Abstract

Pancreatic cancer is an aggressive malignancy, relatively resistant to chemotherapy and radiotherapy, which usually presents late. Disease specific mortality approaches unity despite advances in adjuvant therapy. We present the first reported case of complete pathological response following neoadjuvant therapy in a locally advanced pancreatic adenocarcinoma.

Entities:  

Mesh：

Year:  2007        PMID： 18081235      PMCID： PMC4205465          DOI： 10.3748/wjg.v13.i47.6433

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  15 in total

1.  Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer.

Authors:  Desmond Yip; David Goldstein
Journal:  Cancer Treat Rev       Date:  2005-05       Impact factor: 12.111

Review 2.  Current therapies and advances in the treatment of pancreatic cancer.

Authors:  Andrea Mancuso; Fabio Calabrò; Cora N Sternberg
Journal:  Crit Rev Oncol Hematol       Date:  2006-05-24       Impact factor: 6.312

3.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

Review 4.  Radiochemotherapy in the management of pancreatic cancer--part II: use in adjuvant and locally unresectable settings.

Authors:  Adam Dickler; Ross A Abrams
Journal:  Semin Radiat Oncol       Date:  2005-10       Impact factor: 5.934

5.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

Authors:  Michele Reni; Stefano Cordio; Carlo Milandri; Paolo Passoni; Elisa Bonetto; Cristina Oliani; Gabriele Luppi; Roberto Nicoletti; Laura Galli; Roberto Bordonaro; Alessandro Passardi; Alessandro Zerbi; Gianpaolo Balzano; Luca Aldrighetti; Carlo Staudacher; Eugenio Villa; Valerio Di Carlo
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

6.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.

Authors:  Sean P Cleary; Robert Gryfe; Maha Guindi; Paul Greig; Lloyd Smith; Robert Mackenzie; Steven Strasberg; Sherif Hanna; Bryce Taylor; Bernard Langer; Steven Gallinger
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

7.  Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

Authors:  C G Willett; K Lewandrowski; A L Warshaw; J Efird; C C Compton
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

8.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.

Authors:  T S Lawrence; E Y Chang; T M Hahn; L W Hertel; D S Shewach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

9.  Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

Authors:  Hong Jin Kim; Karen Czischke; Murray F Brennan; Kevin C Conlon
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

10.  Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study.

Authors:  S R Bramhall; W H Allum; A G Jones; A Allwood; C Cummins; J P Neoptolemos
Journal:  Br J Surg       Date:  1995-01       Impact factor: 6.939
View more
  2 in total

Review 1.  Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.

Authors:  Mišo Gostimir; Sean Bennett; Terence Moyana; Harman Sekhon; Guillaume Martel
Journal:  BMC Cancer       Date:  2016-10-10       Impact factor: 4.430

2.  Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases.

Authors:  José Galindo; Mauricio Gabrielli; Juan Francisco Guerra; Juan Carlos Cassina; Marcelo Garrido; Nicolás Jarufe; Yerko Borghero; Jorge Madrid; Pablo Zoroquiain; Juan Carlos Roa; Jorge Martínez
Journal:  World J Surg Oncol       Date:  2013-02-05       Impact factor: 2.754
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.